These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28074765)

  • 1. [Osteoporosis treatment can be discontinued based on an individual assessment].
    Eiken PA; Abrahamsen B
    Ugeskr Laeger; 2017 Jan; 179(2):. PubMed ID: 28074765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
    Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancel the denosumab holiday.
    McClung MR
    Osteoporos Int; 2016 May; 27(5):1677-82. PubMed ID: 26932443
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bisphosphonates first-line pharmacological treatment].
    Wallander M; Ljunggren Ö; Lorentzon M
    Lakartidningen; 2016 Nov; 113():. PubMed ID: 27824394
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
    J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
    Uebelhart B; Rizzoli R; Ferrari SL
    Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Leder BZ; Tsai JN; Jiang LA; Lee H
    Bone; 2017 May; 98():54-58. PubMed ID: 28286299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic setting.
    Roberts J; Castro C; Moore AE; Fogelman I; Hampson G
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):509-15. PubMed ID: 26715263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Osteoporosis Therapies in Combination.
    McClung MR
    Curr Osteoporos Rep; 2017 Aug; 15(4):343-352. PubMed ID: 28667435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
    Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
    Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Matsuoka H; Iwahashi T; Chijimatsu R; Etani Y; Okamura G; Miyama A; Yoshikawa H
    Osteoporos Int; 2018 Jul; 29(7):1627-1636. PubMed ID: 29574517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination and sequential treatment in women with postmenopausal osteoporosis.
    Anastasilakis AD; Polyzos SA; Yavropoulou MP; Makras P
    Expert Opin Pharmacother; 2020 Mar; 21(4):477-490. PubMed ID: 31990595
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
    Gallacher SJ; Dixon T
    Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment.
    Guañabens N; Moro-Álvarez MJ; Casado E; Blanch-Rubió J; Gómez-Alonso C; Díaz-Guerra GM; Del Pino-Montes J; Valero Díaz de Lamadrid C; Peris P; Muñoz-Torres M;
    Endocrine; 2019 Jun; 64(3):441-455. PubMed ID: 30963388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histomorphometric changes following treatment for osteoporosis.
    Moreira CA; Dempster DW
    J Endocrinol Invest; 2017 Sep; 40(9):895-897. PubMed ID: 28550463
    [No Abstract]   [Full Text] [Related]  

  • 20. [Osteoporosis priority: Reduce the number of fractures].
    Roux C
    Presse Med; 2006 Oct; 35(10 Pt 2):1527-8. PubMed ID: 17028516
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.